

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Sihuan Pharmaceutical Holdings Group Ltd.**

**四環醫藥控股集團有限公司**

*(incorporated in Bermuda with limited liability)*

**(Stock code: 0460)**

## **VOLUNTARY ANNOUNCEMENT DRUG REGISTRATION APPROVAL GRANTED FOR TICAGRELOR TABLET (60MG AND 90MG)**

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, the Ticagrelor tablet (60mg and 90mg) (the “**Product**”), an anti-thrombotic drug developed by the Group, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency evaluation on quality and efficiency of generic drugs.

Ticagrelor is a new type of anti-thrombotic drugs used to reduce the incidence of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction with at least one high risk factor for atherothrombotic events. Ticagrelor features quick and strong efficiency without undergoing liver metabolism for its activation. It was recommended by many domestic and foreign treatment guidelines and has great market potential. Ticagrelor tablet is a Class B drug under the 2021 edition of the National Reimbursement Drug List of China.

According to IQVIA, from 2017 to 2020, the sales of Ticagrelor in China increased year by year, reaching RMB420 million, RMB870 million, RMB1,610 million and RMB1,780 million, respectively, with a CAGR of 61.46%; its market size ranked top three in the field of anti-platelet aggregation inhibitor drugs, and the market share increased year by year from 3% in 2017 to 20% in 2020.

The Group focuses on the key layout of anti-thrombotic area. The Product has been granted the Drug Registration Certificate, which will further benefit a majority of patients. At the same time, it will add another blockbuster product to the anti-thrombotic drug pipeline of the Group, thereby benefiting the future market sales and market competition of this drug and exerting positive impacts on the business performance of the Group.

## About Sihuan Pharmaceutical

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical Holdings Group Ltd. is an international pharmaceutical and medical aesthetics company led by innovation, with a leading independent production and research and development technology platform, rich global product pipelines and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to “build itself into a leading medical aesthetics and biopharmaceutical company in China”.

This announcement is being made by the Group on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board  
**Sihuan Pharmaceutical Holdings Group Ltd.**  
**Dr. Che Fengsheng**  
*Chairman and Executive Director*

Hong Kong, 10 January 2022

*As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Mr. Choi Yiau Chong and Ms. Chen Yanling; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.*